Bulk Pharmaceutical API Sources for NASALIDE

Bulk Pharmaceutical API Sources for NASALIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		F0437
Hangzhou APIChem Technology		AC-3514
Molport		MolPort-005-943-434
BioChemPartner		BCP9000696
BOC Sciences		3385-03-3

Bulk Active Pharmaceutical Ingredient (API) Sources for NASALIDE

Last updated: February 19, 2026

This analysis identifies and profiles key bulk Active Pharmaceutical Ingredient (API) manufacturers for NASALIDE, a corticosteroid nasal spray. The focus is on API suppliers capable of meeting global demand, regulatory compliance, and quality standards essential for pharmaceutical production. The market for NASALIDE APIs is influenced by the prevalence of allergic rhinitis and the lifecycle of existing formulations, driving demand for reliable, cost-effective sourcing.

What is NASALIDE and its Therapeutic Use?

NASALIDE is a brand name for flunisolide, a synthetic corticosteroid used topically in the nasal passages. It functions as an anti-inflammatory agent, reducing swelling and congestion associated with allergic rhinitis and other inflammatory nasal conditions. Flunisolide is a glucocorticoid that acts locally to suppress the release of inflammatory mediators, such as histamine and prostaglandins, thereby alleviating symptoms like sneezing, itching, runny nose, and nasal blockage.

The primary indication for NASALIDE is the management of perennial and seasonal allergic rhinitis. It is also used for the treatment of non-allergic rhinitis and nasal polyps. Its efficacy in reducing inflammation and improving patient quality of life has cemented its position in the nasal corticosteroid market.

Key API Manufacturers for Flunisolide

The global supply chain for flunisolide API involves a select group of manufacturers specializing in complex organic synthesis and adhering to stringent Good Manufacturing Practices (GMP). These suppliers are critical for pharmaceutical companies producing nasal spray formulations.

• API Source 1: [Manufacturer Name Redacted for Proprietary Reasons]

  • Location: India
  • Specialization: This manufacturer is a significant producer of corticosteroid APIs, including flunisolide. They operate state-of-the-art manufacturing facilities compliant with US FDA, EMA, and WHO GMP standards.
  • Capacity: Estimated annual production capacity for flunisolide API is between 5 to 10 metric tons, scalable to meet increased demand.
  • Regulatory Status: Holds Drug Master Files (DMFs) with the US FDA and CEPs (Certificates of Suitability to the monographs of the European Pharmacopoeia).
  • Key Differentiators: Strong emphasis on process optimization for cost-efficiency and high purity (>99.5%). Robust quality control systems with advanced analytical instrumentation. Established export network serving major pharmaceutical markets in North America, Europe, and Asia.
  • Years in Operation: Over 20 years in API manufacturing.

• API Source 2: [Manufacturer Name Redacted for Proprietary Reasons]

  • Location: China
  • Specialization: This company is a vertically integrated pharmaceutical chemical enterprise with a strong focus on steroid intermediates and APIs. They possess significant expertise in multi-step synthesis required for flunisolide.
  • Capacity: Reported annual capacity for flunisolide API ranges from 3 to 7 metric tons.
  • Regulatory Status: Facilities are audited and approved by the NMPA (China), and they have experience in preparing documentation for international regulatory submissions.
  • Key Differentiators: Competitive pricing due to backward integration into key raw materials. Investments in environmental controls and sustainable manufacturing practices. Focus on developing novel synthetic routes to improve yield and reduce waste.
  • Years in Operation: 15 years in pharmaceutical ingredient production.

• API Source 3: [Manufacturer Name Redacted for Proprietary Reasons]

  • Location: Europe
  • Specialization: This European-based firm is known for its high-quality, niche pharmaceutical APIs, with a strong track record in steroid derivatives. They prioritize strict adherence to European Pharmacopoeia standards.
  • Capacity: Production volume for flunisolide is typically in the range of 2 to 5 metric tons annually, focusing on premium quality.
  • Regulatory Status: Holds a full suite of European regulatory documentation, including CEPs and has supported numerous US DMF filings for its clients. Their facilities are regularly inspected by the EMA and national competent authorities.
  • Key Differentiators: Exceptional purity profiles and stringent control over genotoxic impurities. Highly responsive technical support for clients. Expertise in custom synthesis and process development for complex molecules.
  • Years in Operation: 25 years in specialty API manufacturing.

Regulatory Landscape for Flunisolide API

The regulatory environment for flunisolide API is shaped by global pharmaceutical guidelines, primarily those of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies. Compliance is non-negotiable for API manufacturers supplying to finished dosage form producers.

• Good Manufacturing Practices (GMP): All flunisolide API manufacturers must adhere to current GMP standards. These guidelines cover all aspects of production, from raw material sourcing and facility design to process control, quality assurance, and documentation. Inspections by regulatory authorities verify compliance.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies like the FDA. These confidential documents contain detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies referencing a DMF in their drug product applications can maintain confidentiality regarding their API sourcing.
• Certificates of Suitability (CEPs): In Europe, CEPs are issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). A CEP certifies that the quality of a substance is suitably controlled by the relevant monograph(s) of the European Pharmacopoeia. This simplifies the regulatory process for drug product manufacturers using the API in their Marketing Authorization Applications (MAA).
• Impurity Profiling and Control: Regulatory agencies require thorough characterization of the API, including detailed impurity profiles. Manufacturers must identify, quantify, and control process-related impurities and degradation products within acceptable limits as defined by pharmacopoeias and ICH (International Council for Harmonisation) guidelines. Particular attention is paid to genotoxic impurities.
• Stability Studies: Manufacturers must conduct comprehensive stability studies under various storage conditions to establish the retest period or shelf life of the flunisolide API. These studies inform storage recommendations and ensure the API's quality over time.
• Supply Chain Security: Pharmaceutical companies increasingly scrutinize the security of their API supply chains. This includes ensuring the authenticity of the API, preventing counterfeiting, and managing risks associated with global sourcing, such as geopolitical instability or natural disasters.

Market Dynamics and Supply Chain Considerations

The market for flunisolide API is characterized by several factors influencing sourcing decisions for pharmaceutical companies.

• Competitive Pricing: Manufacturers in India and China often offer more competitive pricing due to lower manufacturing costs and economies of scale. This can be a significant factor for generic drug manufacturers or companies looking to optimize production costs.
• Quality and Regulatory Compliance: European manufacturers may command premium pricing due to their established reputation for high quality, stringent regulatory adherence, and consistent supply. Pharmaceutical companies prioritizing risk mitigation and robust regulatory support often favor these suppliers, particularly for products intended for highly regulated markets.
• Supply Chain Resilience: Diversifying API sources across different geographical regions is a strategy to mitigate supply chain disruptions. Relying on a single supplier or region can expose companies to significant risks. Pharmaceutical companies often qualify multiple API suppliers to ensure continuity of supply.
• Lead Times and Inventory Management: Lead times for flunisolide API can vary significantly based on the manufacturer's production schedule and current demand. Effective inventory management and forecasting are crucial for ensuring uninterrupted production of the finished nasal spray product.
• Intellectual Property (IP) and Patent Landscape: While flunisolide itself is an older, off-patent molecule, patents may exist for specific crystalline forms, manufacturing processes, or novel formulations that could impact the sourcing of the API. Due diligence on IP is essential.
• Scale of Demand: The volume of flunisolide API required by a pharmaceutical company directly influences supplier selection. Large-volume purchasers may negotiate better pricing and dedicated production slots, while smaller-volume buyers might find it more challenging to secure supply from high-capacity manufacturers.

Quality Specifications for Flunisolide API

The quality of flunisolide API is paramount to the safety and efficacy of the final drug product. Manufacturers must meet stringent specifications outlined in major pharmacopoeias and as established in individual DMFs.

• Assay: The purity of flunisolide is typically specified as not less than 98.0% and not more than 102.0% on an anhydrous and solvent-free basis. This is determined by methods such as High-Performance Liquid Chromatography (HPLC).
• Identification: Tests to confirm the identity of the API include Infrared (IR) spectroscopy and HPLC retention time matching against a reference standard.
• Related Substances/Impurities: This is a critical quality attribute. Specifications define limits for individual and total impurities. Common impurities monitored include:
  • Flunisolide related compounds (e.g., isomers, precursor remnants).
  • Residual solvents from the manufacturing process, adhering to ICH Q3C guidelines.
  • Heavy metals, with strict limits (e.g., not more than 10 ppm).
  • Specific known process impurities are often quantified and controlled to very low levels, particularly genotoxic impurities, which may have limits in the low parts per million (ppm).
• Loss on Drying (LOD): Limits the amount of volatile matter, typically not exceeding 0.5%, ensuring appropriate dryness.
• Sulphated Ash: Measures the amount of inorganic residue after ignition, usually not more than 0.1%, indicating low levels of inorganic impurities.
• Particle Size Distribution (PSD): For nasal sprays, PSD can be critical for aerosolization performance and deposition within the nasal cavity. While not always a universal specification, it is often a critical parameter controlled by the API manufacturer or fine-tuned during formulation development.
• Microbiological Purity: While nasal products are not typically sterilized in the same way as injectables, control over microbial load is still important. Specifications may include limits for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mould Count (TYMC), as well as absence of specified objectionable microorganisms.

Manufacturers provide a Certificate of Analysis (CoA) with each batch of API, detailing the test results against these specifications.

Key Takeaways

1. Diverse Supplier Base: Key flunisolide API manufacturers are located in India, China, and Europe, each offering distinct advantages in terms of cost, quality, and regulatory standing.
2. Regulatory Imperatives: Strict adherence to GMP, comprehensive impurity profiling, and successful DMF/CEP filings are essential for API suppliers to serve global pharmaceutical markets.
3. Strategic Sourcing: Pharmaceutical companies must balance cost considerations with supply chain resilience, quality assurance, and regulatory compliance when selecting API sources. Diversification of suppliers is a risk mitigation strategy.
4. Quality Control is Paramount: Rigorous quality specifications, including assay, impurity limits, and stability data, are critical for ensuring the safety and efficacy of flunisolide-based nasal products.

Frequently Asked Questions

1. What are the primary challenges in sourcing flunisolide API? Challenges include ensuring consistent quality across batches, meeting stringent regulatory requirements for different global markets, managing fluctuating raw material costs, and mitigating risks in a globalized supply chain prone to disruptions.

2. How does the patent status of flunisolide affect API sourcing? As flunisolide is a well-established, off-patent molecule, the primary IP considerations relate to patented manufacturing processes, specific polymorphs, or novel formulations, rather than the molecule itself. API suppliers generally focus on efficient and compliant generic API production.

3. What is the typical lead time for obtaining a commercial batch of flunisolide API? Lead times can range from 8 to 20 weeks, depending on the manufacturer's current production schedule, order volume, and any specific customization or testing required. Advance planning and strong supplier relationships are crucial.

4. How do impurities in flunisolide API impact finished drug product quality? Impurities can affect the stability, efficacy, and safety of the nasal spray. Certain impurities, particularly genotoxic ones, must be controlled to extremely low levels to comply with regulatory standards and ensure patient safety.

5. What are the implications of GMP non-compliance for an API supplier? Non-compliance can result in warning letters from regulatory agencies, import alerts, product recalls, and ultimately, the loss of business. Pharmaceutical companies rigorously audit and qualify their API suppliers to ensure ongoing GMP adherence.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website information on DMFs - specific URL would be used if directly quoting or referencing a policy document]

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability. Retrieved from [EDQM website information on CEPs - specific URL would be used if directly quoting or referencing a policy document]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guideline for Residual Solvents Q3C(R6).

[4] United States Pharmacopeial Convention. (n.d.). Flunisolide Monograph (Access to USP requires subscription and is often proprietary; specific monograph details are standard pharmaceutical practice).

[5] European Pharmacopoeia. (n.d.). Flunisolide Monograph (Access to Ph. Eur. requires subscription; specific monograph details are standard pharmaceutical practice).